published meta-analysis   sensitivity analysis   studies

remdesivir in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsPINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30] 1.01[0.02; 51.30]PINETREE (GS-US-540-9012), 202110%562NAnot evaluable deathsdetailed resultsPINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30] 1.01[0.02; 51.30]PINETREE (GS-US-540-9012), 202110%562NAnot evaluable hospitalization or deathdetailed resultsPINETREE (GS-US-540-9012), 2021 0.13 [0.03; 0.58] 0.13[0.03; 0.58]PINETREE (GS-US-540-9012), 202110%562NAnot evaluable hospitalizationdetailed resultsPINETREE (GS-US-540-9012), 2021 0.28 [0.10; 0.77] 0.28[0.10; 0.77]PINETREE (GS-US-540-9012), 202110%562NAnot evaluable AE leading to drug discontinuationdetailed resultsPINETREE (GS-US-540-9012), 2021 0.40 [0.08; 2.09] 0.40[0.08; 2.09]PINETREE (GS-US-540-9012), 202110%562NAnot evaluable serious adverse eventsdetailed resultsPINETREE (GS-US-540-9012), 2021 0.25 [0.09; 0.69] 0.25[0.09; 0.69]PINETREE (GS-US-540-9012), 202110%562NAnot evaluable adverse eventsdetailed resultsPINETREE (GS-US-540-9012), 2021 0.85 [0.61; 1.19] 0.85[0.61; 1.19]PINETREE (GS-US-540-9012), 202110%562NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-03-28 19:51 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 510 - roots T: 290